RESUMO
Purpose: A novel fixed-dose combination of 150 mg of econazole with 6 mg of benzydamine formulated in vaginal ovules was investigated in a randomised, double-blind, four-parallel group, tolerability, and pharmacokinetic Phase I study in healthy women. Methods: The fixed-dose combination was compared to econazole and benzydamine single-drug formulations and with placebo after daily applications for 3 consecutive days. Safety and tolerability were evaluated recording the adverse drug reactions, local and general tolerability scores, clinical laboratory assays, and vital signs. Econazole, benzydamine, and its metabolite benzydamine N-oxide pharmacokinetics were investigated after single and multiple applications. Results: Local reactions were generally absent. Pruritus and pain at the application site were infrequently reported. According to the subjects' evaluations, the overall tolerability of the ovules was rated as excellent or good. No significant effect of any treatment on laboratory parameters, vital signs, body weight, vaginal pH, or ECG was observed. Very low econazole, benzydamine, and benzydamine-N-oxide concentrations were measured in plasma, though quantifiable in almost all samples. Conclusion: The tested fixed-dose combination showed a good safety profile consistently with the known tolerability of both active substances. In addition, the confirmed low bioavailability of the drugs excludes the possibility of any accumulation effects and limits the risk of undesired systemic effects. This trial is registered at ClinicalTrials.gov with the identifier NCT02720783 last updated on 07 February 2017.
Assuntos
Antifúngicos/farmacocinética , Benzidamina/farmacocinética , Sistemas de Liberação de Medicamentos/instrumentação , Econazol/farmacocinética , Vagina/efeitos dos fármacos , Administração Oral , Adulto , Antifúngicos/administração & dosagem , Área Sob a Curva , Benzidamina/administração & dosagem , Benzidamina/análogos & derivados , Método Duplo-Cego , Esquema de Medicação , Combinação de Medicamentos , Econazol/administração & dosagem , Feminino , Voluntários Saudáveis , Humanos , Pessoa de Meia-Idade , Adulto JovemRESUMO
Methylene blue-MMX® tablets are proposed as an aid for detection and visualisation of adenomas and carcinomas in patients undergoing colonoscopy, by improving their detection rate and highlighting the presence of the intestinal dysplastic lesions. Single total doses of 100 and 200â¯mg were administered to healthy volunteers undergoing a bowel cleansing preparation and a full colonoscopy to investigate the colonic staining. The pharmacokinetics of methylene blue and the safety after exposure to the tablets were also investigated. With 200â¯mg, the best staining, assessed as the sum of acceptable and good staining, was achieved in the ascending colon and rectosigmoid (75% subjects each), the transverse and the descending colon (approximately 63% each). Absence of staining or overstaining were reported for no colonic region of interest in any subject. Similar results were observed in the 100â¯mg dose group. Methylene blue blood concentrations reached a peak (Cmax) in a median time (Tmax) of 12â¯h with 100â¯mg and 16â¯h with 200â¯mg. AUC0-t was 10.7⯱â¯6.7⯵g/mLxh after 100â¯mg and 25.2⯱â¯7.4⯵g/mLxh after 200â¯mg. Half-life ranged between 9 and 22â¯h after the lower dose and between 6 and 26â¯h after the higher dose. The cumulative urinary excretion was about 28% after 100â¯mg and about 39% after 200â¯mg up to 60 h post-dose. The overall frequency of adverse events after single dose of the test product administered along with a bowel cleansing preparation was 39%, but only one was related to the test product: abnormal transaminases. The most frequent adverse event was a transient polyuria (17%). One serious adverse event (gastrointestinal haemorrhage) led the subject to study discontinuation and hospitalisation and another subject withdrew the study due to one adverse event (haematemesis). Either event was not related to methylene blue.
Assuntos
Colo , Colonoscopia/métodos , Azul de Metileno , Coloração e Rotulagem , Administração Oral , Adulto , Disponibilidade Biológica , Catárticos/uso terapêutico , Colo/diagnóstico por imagem , Colo/patologia , Neoplasias do Colo/diagnóstico por imagem , Neoplasias do Colo/patologia , Corantes/administração & dosagem , Corantes/efeitos adversos , Corantes/farmacocinética , Relação Dose-Resposta a Droga , Voluntários Saudáveis , Humanos , Aumento da Imagem/métodos , Aumento da Imagem/normas , Masculino , Azul de Metileno/administração & dosagem , Azul de Metileno/efeitos adversos , Azul de Metileno/farmacocinética , Pessoa de Meia-Idade , Avaliação de Resultados em Cuidados de Saúde , Melhoria de Qualidade , Eliminação Renal , Coloração e Rotulagem/métodos , Coloração e Rotulagem/normasRESUMO
PURPOSE: To study the effects of terlipressin (TP) infusion on systemic perfusion, estimated with pulsed-wave Doppler ultrasonography of systemic arteries, in a population of extremely low birth-weight (ELBW) preterm infants with vasoactive-resistant ductus arteriosus. METHODS: This prospective, observational cohort included, during five years, 12 ELBW infants with hemodynamically significant patent ductus arteriosus and absent or reversed diastolic flow at Doppler ultrasonography of systemic arteries, despite treatment and high-dose vasoactive support. We measured flow velocity of the anterior cerebral, right renal, and superior mesenteric arteries before and after TP infusion. Changes were evaluated by Spearman's rho coefficient analysis, Wilcoxon signed-rank, and Friedman test. RESULTS: Time-averaged mean velocity of the renal artery (P = .028) increased, while renal pulsatility (P = .010) and resistance (P = .004) indexes, and cerebral artery resistance index (P = .021) decreased after TP infusion. Time-averaged mean velocity of the anterior cerebral artery proportionately increased with dopamine dose (rho = 0.678; P = .015), but showed opposite shifts after TP (rho = -0.662; P = .024). CONCLUSIONS: These changes suggest that TP may improve systemic perfusion in the ELBW infants with vasoactive-resistant ductus arteriosus.
Assuntos
Artérias Cerebrais/efeitos dos fármacos , Permeabilidade do Canal Arterial/fisiopatologia , Lipressina/análogos & derivados , Artéria Mesentérica Superior/efeitos dos fármacos , Artéria Renal/efeitos dos fármacos , Ultrassonografia Doppler de Pulso/métodos , Velocidade do Fluxo Sanguíneo/efeitos dos fármacos , Artérias Cerebrais/diagnóstico por imagem , Estudos de Coortes , Permeabilidade do Canal Arterial/tratamento farmacológico , Feminino , Humanos , Recém-Nascido de Peso Extremamente Baixo ao Nascer , Recém-Nascido , Recém-Nascido Prematuro , Doenças do Prematuro , Lipressina/farmacologia , Masculino , Artéria Mesentérica Superior/diagnóstico por imagem , Projetos Piloto , Estudos Prospectivos , Artéria Renal/diagnóstico por imagem , Terlipressina , Ultrassonografia Doppler de Pulso/efeitos dos fármacos , Vasoconstritores/farmacologiaRESUMO
OBJECTIVES: To investigate the pharmacokinetics, safety and preliminary effectiveness of ultra-low-dose estriol vaginal gel formulations (20 µg/g (T1) and 50 µg/g (T2)) compared to Ovestinon® (estriol 500 µg/0.5 g (R)) and placebo in postmenopausal women. METHODS: Forty-three volunteers were randomly assigned to received T1, T2, R or placebo once daily for 21 days. Absorption of estriol after single and multiple administration was analyzed. Cytological changes in the vagina, tolerability and safety were also investigated. RESULTS: Thirty-six women were included in the pharmacokinetic analysis. Systemic absorption was lower with test formulations (AUC0-t: 171.65 ± 80.18 (T1) and 406.75 ± 199.53 (T2) pg/ml × h) than with Ovestinon® (1221.97 ± 549.06 pg/ml × h). Estriol exposure of the test formulations after multiple administration (AUCss: 36.33 ± 30.52 (T1) and 73.71 ± 46.86 (T2) pg/ml × h) was significantly lower than after single-dose administration and not significantly different between them. In contrast, the exposure after repeated administration of Ovestinon® was considerable and not statistically different from levels after single administration. All estriol formulations produced similar improvement in the vaginal maturation value, while placebo showed a small and not significant change. Overall safety and acceptability were good. CONCLUSIONS: Estriol 20 and 50 µg/g formulations, while showing a comparable capacity for reversing vaginal atrophy, present a highly favorable safety profile, producing a very low systemic absorption of estriol and significantly lower than that of Ovestinon®.
Assuntos
Estriol/administração & dosagem , Estriol/farmacocinética , Géis , Pós-Menopausa , Administração Intravaginal , Idoso , Atrofia , Disponibilidade Biológica , Estriol/efeitos adversos , Feminino , Humanos , Pessoa de Meia-Idade , Placebos , Vagina/patologia , Cremes, Espumas e Géis Vaginais/uso terapêutico , Doenças Vaginais/tratamento farmacológicoRESUMO
Experience with terlipressin (TP) in the neonatal field is scarce. We describe the effects of TP on pulmonary circulation, studied with echocardiography, in an asphyxiated septic cooled infant with pulmonary hypertension (PH) who developed catecholamine-resistant hypotension and exacerbation of PH shortly after the beginning of the rewarming. TP was added to norephinephine and adrenaline infusions at the dose of 0.02 mg kg(-1) every 6 h, because of refractory hypotension and oliguria. After 10 min, blood pressure dramatically and definitely increased, and urinary output was re-established after 60 min. Echocardiographic evaluation 30 min after the second bolus of TP showed unchanged velocity of the tricuspidal valve regurgitation and improved biventricular functional indexes respect to the pre-treatment assessment. TP was continued for 12 h (three doses) without significant adverse effect except for a transient increase in troponin levels. Addition of TP boluses to catecholamine infusion in our newborn was effective in increasing systemic vascular resistance without increasing pulmonary vascular resistance, successfully reversing the hemodynamics of severe PH, and suggesting a potential primary vasodilator effect on pulmonary circulation. Transient increase of troponin levels during TP treatment confirms the risk of excessive coronary vasoconstriction when TP boluses are added to high dose catecholamines.
Assuntos
Anti-Hipertensivos/farmacologia , Hipertensão Pulmonar/tratamento farmacológico , Lipressina/análogos & derivados , Circulação Pulmonar/efeitos dos fármacos , Anti-Hipertensivos/administração & dosagem , Asfixia Neonatal , Progressão da Doença , Epinefrina/administração & dosagem , Humanos , Hipertensão Pulmonar/fisiopatologia , Hipotermia Induzida , Recém-Nascido , Lipressina/administração & dosagem , Lipressina/farmacologia , Masculino , Norepinefrina/administração & dosagem , Choque , Terlipressina , Insuficiência da Valva Tricúspide/diagnóstico por imagem , Troponina/sangue , Ultrassonografia , Resistência Vascular/efeitos dos fármacos , Vasoconstritores/administração & dosagemRESUMO
AIM: To review the working principles of thromboelastography and evaluate the current knowledge about the possibility of its implementation in the neonatal intensive care unit setting. METHOD: Thorough search of the literature in the PubMed database (until May 31, 2012) concerning Thromboelastography (TEG) and/or Thromboelastometry (ROTEM) use in the newborn infant. RESULTS: Neonatal data are limited to a small number of healthy subjects and virtually absent in the extreme premature infant. Healthy newborns exhibit age dependent accelerated initiation and propagation of coagulation despite prolonged standard plasma coagulation test results, whereas clot firmness and fibrinolysis are similar to adult values. Several neonatal pathological conditions (e.g. sepsis; hypothermia) are linked with substantial changes in the thromboelastographic parameters. CONCLUSIONS: The current knowledge is too limited to express a definitive indication on the reliability of the use of viscoelastic point of care analyzer in the neonatal intensive care unit setting. However, their potential use not only as a diagnostic tool, but also to guide the transfusion therapy requires careful consideration.
Assuntos
Neonatologia/métodos , Tromboelastografia/estatística & dados numéricos , Adulto , Coagulação Sanguínea/fisiologia , Estudos de Coortes , Humanos , Recém-Nascido , Modelos Biológicos , Reprodutibilidade dos Testes , Tromboelastografia/métodosRESUMO
This retrospective study was carried out at eight Neonatal Intensive Care Units (NICU) Centers worldwide on 33 newborns presenting at birth with pleural, pericardial, or abdominal chylous effusions. Diagnosis of chylous effusion is based on findings of fluid with a milk-like appearance, a concentration of triglycerides in pleural effusion >1.1 mmol/l, and a total cell count >1,000 cells/ml with a predominance of >80% lymphocytes. Thirty-three newborns met the inclusion criteria and were studied. Six subjects who presented at birth with fetal effusion were treated by in-utero pleuro-amniotic shunt. Five of these patients are alive at follow-up. At birth, pleural drainage was performed in 29/33 patients and abdominal drainage was carried out in 3/33. Total parenteral nutrition (TPN) was given to 32/33 patients; 19/23 patients were fed a medium-chain triglycerides (MCT). No adverse effects were observed. Eight patients were treated with Octreotide at dosages ranging from 1 to 7 mcg/kg/hour for 8 to 35 days. All patients showed decreased chylous production. Two patients were treated by pleurodesis. Twenty-two babies are alive after at least 6 months follow-up, 9/33 are deceased, and 2 were lost to follow-up. Clinical conditions of survivors are basically good except for lung involvement [chronic lung disease (CLD) or lung lymphangiectasia] and lymphedema. All patients were using a MCT diet at follow-up with good control of chylous effusion. Visceral chylous effusions of the fetus and neonate are rare disorders, and there currently is only partial agreement on decision-making strategies. We suggest the need for an international prospective trial in an effort to establish the efficacy and effectiveness of diagnostic and therapeutic options described in this article.
Assuntos
Quilotórax/congênito , Ascite Quilosa/congênito , Quilotórax/diagnóstico , Quilotórax/terapia , Ascite Quilosa/diagnóstico , Ascite Quilosa/terapia , Feminino , Humanos , Recém-Nascido , Masculino , Octreotida/uso terapêutico , Estudos Retrospectivos , Triglicerídeos/administração & dosagemRESUMO
Methylene blue-MMX tablets are proposed as colonic diagnostic staining. Methylene blue taken prior to colonoscopy is expected to provide an effective staining of colonic and rectal mucosa leaving unstained the dysplastic or polypoid areas. The present single dose, open-label study investigated the safety of methylene blue after single oral doses of 200 and 400mg in healthy volunteers. The absolute bioavailability was also investigated after the intake of 2L of bowel cleansing preparation in 2h and by comparing the dose of 200mg with a single iv dose of 100mg in the same subjects. Only non-serious adverse events occurred. Related events occurred to 8/22 subjects. Most of the events were mild and transient. Abnormal transaminases, gastrointestinal disorders and dysuria frequency were 13.6%. After intake of the laxative and the oral dose of 200mg, systemic exposure to methylene blue was shown in all subjects with concentrations increasing for 12h. The peak was reached in a median of 16 h. Peak blood concentration did not increase proportionally with the dose. AUC(0-t) was 32.94 µg/mL × h after 200mg and 38.08 µg/mL × h after 400mg. Half life ranged between 14 and 27 h after the lower dose and between 6 and 26 h after the higher dose. The cumulative excretion was about 40% of the injected dose, 39.67% after 200mg and 23.48% after 400mg. Absolute bioavailability of methylene blue calculated as ratio between AUC(0-t) oral/iv corrected for the dose was on average F(abs)=139.19 ± 52.00%.
Assuntos
Colonoscopia/métodos , Tolerância a Medicamentos , Mucosa Intestinal/metabolismo , Azul de Metileno/farmacocinética , Administração Oral , Adulto , Disponibilidade Biológica , Estudos Cross-Over , Relação Dose-Resposta a Droga , Inibidores Enzimáticos/administração & dosagem , Inibidores Enzimáticos/farmacocinética , Feminino , Seguimentos , Humanos , Mucosa Intestinal/efeitos dos fármacos , Masculino , Azul de Metileno/administração & dosagem , Pessoa de Meia-Idade , Valores de Referência , Estudos Retrospectivos , Comprimidos , Adulto JovemAssuntos
Fungemia/microbiologia , Gastroenteropatias/terapia , Doenças do Prematuro/terapia , Metemoglobinemia/microbiologia , Saccharomyces , Fatores Biológicos/efeitos adversos , Candida albicans/isolamento & purificação , Candidíase/microbiologia , Retardo do Crescimento Fetal/complicações , Humanos , Recém-Nascido , MasculinoRESUMO
A strongly positive tuberculin skin reaction (> 1.5 cm2) was observed during the acute phase of the illness in 11 children with Kawasaki disease (KD), but not in control pediatric patients with other febrile infections (41 patients) or diseases similar to KD (9 patients). The cutaneous sensitivity to intermediate strength [5 tuberculin units (TU)] purified protein derivative (PPD) inoculation had completely disappeared by the second monthly checkup. Peripheral blood T lymphocytes from KD subjects proliferated vigorously and produced significant amounts of IL-2 in response to the stimulation elicited by 0.05 TU/mL of PPD. In contrast, the proliferative response of, and IL-2 release by, control T cells was within background values. Mounting laboratory evidence suggests that heat shock proteins (HSP) may be involved in the pathogenesis of KD. Our clinical and experimental data may, therefore, have been due to immunologic cross-reactivity between mycobacterial derived HSP65 and its human homologue HPS63 (self P1 antigen). Despite the low number of patients investigated, our findings suggest that the tuberculin skin test and its in vitro correlates (T cell mitogenesis and IL-2 production) could provide simple and reliable diagnostic tools for identifying atypical forms of KD, or vice versa, in subjects not vaccinated against tuberculosis.
Assuntos
Linfocinas/biossíntese , Síndrome de Linfonodos Mucocutâneos/diagnóstico , Linfócitos T/metabolismo , Teste Tuberculínico , Divisão Celular/imunologia , Pré-Escolar , Feminino , Humanos , Lactente , Masculino , Síndrome de Linfonodos Mucocutâneos/imunologia , Síndrome de Linfonodos Mucocutâneos/metabolismo , Linfócitos T/imunologiaRESUMO
Very high levels of sCD30, a glycoprotein surface antigen expressed by T lymphocytes and other mononuclear cells of the immune system, were found in serum samples from 10 children with typical Kawasaki disease (KD), but not in blood specimens from a vast cohort of paediatric control subjects. These data strongly support an involvement of CD30 T cells in the immune processes which take place at the level of lymphoid organs during the acute phase of KD.
Assuntos
Antígeno Ki-1/sangue , Antígeno Ki-1/imunologia , Síndrome de Linfonodos Mucocutâneos/imunologia , Pré-Escolar , Ensaio de Imunoadsorção Enzimática , Feminino , Humanos , Lactente , Masculino , Linfócitos T/imunologiaRESUMO
It is now well established that the CD30 glycoprotein is a surface antigen expressed by activated T cells producing T-helper (Th)-2-type lymphokines. Mounting laboratory evidence, however, suggests that CD30 expression is not confined to a functionally restricted subset of T cells, but also identifies activated cells with a Th-1 and Th-0 pattern of cytokine secretion. CD30-bearing T lymphocytes release a soluble form of the molecule (sCD30), which can be detected both in vitro and in vivo. In the present study, very high levels of sCD30 were found in colostrum from 20 puerperal women, but not in autologous and heterologous (nonpregnant women) blood samples. These data strongly support an involvement of CD30+ T cells in the immune processes which take place at the level of the mammary gland during pregnancy and lactation. Passively transferred immune components such as immunoglobulins, cytokines, macrophages, natural killer cells, granulocytes and memory/activated T cells, all of which may help the baby to fight off infections, have been revealed in human breast milk. However, how Th-2-type cytokine-secreting T cells or other T-cell types help to endow the congenitally immunocompromised newborn infant with extrinsic immunological support remains an open question.
Assuntos
Colostro/imunologia , Antígeno Ki-1/análise , Ensaio de Imunoadsorção Enzimática , Feminino , Citometria de Fluxo , Humanos , Imunidade Materno-Adquirida , Recém-Nascido , Lactação/imunologia , Gravidez , Linfócitos T/imunologiaRESUMO
The biological role of T cell receptor (TCR) gamma delta bearing cells is not yet fully understood. We studied 12 children with Bordetella pertussis infection and 12 age- and sex-matched healthy controls. Patients with whooping-cough yielded significantly lower relative and absolute numbers of blood TCR-gamma delta + cells than normal controls (both p < 0.001). It is suggested that the depletion of circulating gamma delta T cells in patients with Bordetella pertussis infection might be the result of the dispatch of these cells to the site of inflammation, i.e. the bronchial mucosa. Interestingly, other human lung diseases, such as allergic bronchial asthma and sarcoidosis display similar pulmonary phenotypical features.
Assuntos
Receptores de Antígenos de Linfócitos T gama-delta/sangue , Coqueluche/imunologia , Brônquios/imunologia , Estudos de Casos e Controles , Criança , Pré-Escolar , Feminino , Humanos , Inflamação , Contagem de Linfócitos , Masculino , Mucosa/imunologia , Receptores de Antígenos de Linfócitos T gama-delta/imunologiaAssuntos
Síndrome de Linfonodos Mucocutâneos/diagnóstico , Síndrome de Linfonodos Mucocutâneos/imunologia , Mycobacterium tuberculosis/imunologia , Teste Tuberculínico , Anticorpos Antibacterianos/sangue , Pré-Escolar , Feminino , Proteínas de Choque Térmico/imunologia , Humanos , Lactente , MasculinoRESUMO
The proportion of T lymphocytes, mainly CD4 positive, co-expressing the CD40 ligand (CD40-L) was significantly greater (P = 0.001) in the colostrum of 10 breast-feeding mothers than in either autologous or heterologous blood. This surface glycoprotein is a T cell molecule involved in B cell isotype switching and immunoglobulin production with its natural counter-receptor, CD40, expressed by both adult and infant B lymphocytes. As the T cells of newborn infants fail to express the CD40-L when stimulated in vitro, the in vivo upregulation on milk T lymphocytes may be one of the mechanisms through which the mother transfers immune protection to the suckling infant.